Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Mitoxantrone × Endocrine × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 5 Lymphoid 2 Head & Neck 1 Endocrine 1

Conditions

Thyroid Cancer, Papillary 1

Interventions

Octreotide 5 lanreotide 4 Everolimus 3 Dexmedetomidine 3 Cabergoline 3 pasireotide 2 Phenoxybenzamine 2 trametinib 1 testosterone enanthate 1 surufatinib 1 selpercatinib 1 pralsetinib 1 pegvisomant 1 lutetium Lu 177 dotatate 1 lenvatinib 1 larotrectinib 1 gadoteridol 1 gadoterate meglumine 1 gadolinium ethoxybenzyl DTPA 1 gadodiamide 1 gadobutrol 1 gadobenic acid 1 entrectinib 1 dabrafenib 1 candesartan 1 arginyllysine 1 anlotinib 1 Vitamin D 1 Trimethoprim 1 Thyroid (USP) 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07354698 2026-01-21

MHI

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Phase 4 Not yet recruiting

EndocrineHead & Neck

Thyroid Cancer, Papillary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡